Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the five brokerages that are currently covering the stock, Marketbeat ...
In a report released today, David Amsellem from Piper Sandler maintained a Buy rating on Amneal Pharmaceuticals (AMRX – Research Report), with ...
Amneal Pharmaceuticals (NYSE:NASDAQ:AMRX), a commercial-stage biopharmaceutical company with a market capitalization of $2.53 billion, has been positioning itself for a new phase of multi-year ...
In trading on Monday, shares of Amneal Pharmaceuticals Inc (Symbol: AMRX) crossed below their 200 day moving average of $7.76, changing hands as low as $7.68 per share. Amneal Pharmaceuticals Inc ...
Amneal Pharmaceuticals (AMRX) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the ...
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today ...
Chicago, IL – February 3, 2025 – Today, Zacks Equity Research discusses Corcept Therapeutics CORT, Amneal Pharmaceuticals AMRX, Dyne Therapeutics DYN, Nektar Therapeutics NKTR and Cardiol ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback